People · Operator
Named in public records as an officer, director or promoter · active 2022–2026 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gilgamesh Pharma Inc. | — | Pharmaceuticals | Series C | $72.7M | $10.8M | 2026 |
| Gilgamesh Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $51.8M | $223.1M | 2022 |
Phil Skolnick at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Phil Skolnick on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Berman | 2 | 4 |
| Amy Kruse | 2 | 4 |
| Jonathan Sporn | 2 | 2 |
| Andrew Kruegel | 2 | 2 |
| Zia Huque | 1 | 3 |
| Laszlo Kiss | 1 | 1 |
| Dalibor Sames | 1 | 1 |
| Jonathan Sporn, M.D. | 1 | 1 |
| Andrew Kruegel, Ph.D. | 1 | 1 |
| Thomas Kevin Murphy, Ph.D. | 1 | 1 |
| Gerard Marek | 1 | 1 |
| Yoni Falkson | 1 | 1 |
| Thomas Kevin Murphy | 1 | 1 |
| Gaetano Kevin Crupi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.